Hepatology Highlights

Alyson Kaplan, Robert S. Brown, Adam Buckholz, Thuy‐Van P. Hang, Preeti A. Reshamwala, Jessica L. Maiers, Robert E. Schwartz, Wei Zhang, Shalil Khanal, Enis Kostallari, Adebowale O. Bamidele, Amani Lee, Enis Kostallari, Mati Ullah Dad Ullah, Daryl T.Y. Lau, Davide Povero, Nabeel Wahid, Russell Rosenblatt – 20 October 2021

LiverLearning®: 2021 Webinar: AASLD’s Thought Leaders Series: How I Manage My Practice

This 60-minute discussion, held Wednesday, October 20 th and hosted by AASLD President, Dr. Ray Chung, FAASLD of Massachusetts General, included interviews with NAFLD/NASH experts, Dr. Mary Rinella, FAASLD of Northwestern University and Dr. Anna Mae Diehl, FAASLD of Duke University. Our experts delved into how they manage their practices in fatty liver, how their institutions and multidisciplinary teams work together, diagnostic and treatment solutions to NAFLD, and more. This webinar is the first of a new program, AASLD's Thought Leaders Series: How I Manage My Practice .

Malnutrition in Biliary Atresia: Assessment, Management, and Outcomes

Julia M. Boster, Amy G. Feldman, Cara L. Mack, Ronald J. Sokol, Shikha S. Sundaram – 19 October 2021 – Children with biliary atresia (BA), particularly infants, are at high risk for malnutrition attributed to a multitude of factors, including poor oral intake and intolerance of enteral feeding, fat malabsorption, abnormal nutrient metabolism, and increased caloric demand. Malnutrition and sarcopenia negatively impact outcomes in BA, leading to higher pretransplant and posttransplant morbidity and mortality.

Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis

Alexa M. Giammarino, He Qiu, Kishen Bulsara, Sabrina Khan, Yu Jiang, Ben L. Da, David E. Bernstein, Sanjaya K. Satapathy – 19 October 2021 – In order to determine the relationship between socioeconomic deprivation and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH), we retrospectively reviewed the electronic medical records of 1,430 patients in a large tertiary health care network in New York. These patients underwent liver biopsy over a 10‐year period and were included in our study if they had evidence of NAFLD/NASH on liver biopsy.

Subscribe to